Meanwhile, the transcriptional levels of CMTM7 can predict the immunotherapy response better than those of PD-1 and PD-L1, suggesting that CMTM7 is a novel biomarker that can recognize the immune-hot TME and predict the effective therapeutic response of immunotherapy in BRCA, implying that measuring the CMTM7 levels of breast cancers could guide the therapeutic schedule. This evidence concerns the gene CD274 and breast carcinoma.